Compare LXU & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXU | OMER |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | United States |
| Employees | 513 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.0M | 821.7M |
| IPO Year | 2006 | 2008 |
| Metric | LXU | OMER |
|---|---|---|
| Price | $13.63 | $11.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $10.94 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 788.8K | 751.6K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.93 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $615,208,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $39.51 | ★ N/A |
| Revenue Growth | ★ 17.77 | N/A |
| 52 Week Low | $4.88 | $2.95 |
| 52 Week High | $14.65 | $17.65 |
| Indicator | LXU | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 78.19 | 43.42 |
| Support Level | $7.36 | $11.09 |
| Resistance Level | N/A | $11.90 |
| Average True Range (ATR) | 0.70 | 0.48 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 80.44 | 13.91 |
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.